Rtw Biotech Opportunities (LSE:RTW)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMRTW

RNS Number : 9137L

RTW Venture Fund Limited

15 January 2021

LEI: 549300Q7EXQQH6KF7Z84

15 January 2021

RTW Venture Fund Limited

(the "Company")

Announcement of Share Issuance

Further to publication of the Company's 31 December 2020 net asset value, released on 15 January 2021, and taking into consideration interim performance of the Company's portfolio in January 2021, the Company confirms that it may issue new ordinary shares at a price of US$2.12 per new ordinary share, reflecting an 8.2 per cent. premium to the 31 December 2020 net asset value.

The Company intends to issue new ordinary shares on this basis until 19 January 2021. Investors wishing to participate in this issuance should reflect their interest to james.e.bouverat@jpmorgan.com and carrie.fox@jpmorgan.com at J.P. Morgan Cazenove.

For Further Enquiries

   RTW Investments, LP                                          +1 (646) 343 9280 

Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

   J.P. Morgan Cazenove                                     +44 (0)20 7742 4000 

William Simmonds

Jeremie Birnbaum (Corporate Finance)

James Bouverat (Sales)

Carrie Fox

   Ocorian (Company Secretary)                       +44 (0)1481 742 642 

Kevin Smith

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEBAMATMTJBBPB

(END) Dow Jones Newswires

January 15, 2021 10:39 ET (15:39 GMT)